The Right to Genetic Ignorance
By Editorial,
New Scientist
| 09. 06. 2013
The age of genomic medicine is dawning. Whole-genome sequencing is starting to transform the diagnosis of rare inherited diseases, and within a few decades it could be a routine part of medical care (see "
Your genomic future: Personalised medicine is here ").
But an ethical row has broken out on this new frontier. In June, the American College of Medical Genetics and Genomics published guidelines arguing that people having their genome sequenced should be informed if the results show defects in any of 56 genes linked to 24 serious diseases (
Genetics in Medicine, vol 15, p 565).
The idea is to flag up known risks that could be mitigated – although in some cases that could require drastic action. The list includes mutations in the
BRCA1 gene that earlier this year prompted movie star
Angelina Jolie to have a double mastectomy to reduce her risk of developing breast cancer.
The intentions are laudable, but routine disclosure may not always be welcome. Imagine that you are seeking the cause of a mysterious condition that has brought your...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...